Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

5871 - Residual Cancer burden as a prognostic factor in a large series of Neoadjuvant chemotherapy. Subgroup analysis per molecular surrogated subtypes


29 Sep 2019


Poster Display session 2


Tumour Site

Breast Cancer


Catalina Falo


Annals of Oncology (2019) 30 (suppl_5): v55-v98. 10.1093/annonc/mdz240


C. Falo1, S. Fernández2, E. Garrigós2, A.C. Vethencourt Casado3, S. Vázquez4, A. Stradella5, S. Recalde5, M.J. Pla2, M. Campos6, A. Gumà7, R. Ortega7, A. Petit8, T. Soler9, J. Perez10, E. Fernandez6, M.S. Bergamino1, S. Pernas Simon11, M.J. Gil12, J. Ponce6, A. Garcia Tejedor6

Author affiliations

  • 1 Medical Oncology, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), 08908 - Hospitalet de Llobregat/ES
  • 2 Gynaecology, Hospital Universitari Bellvitge, 08907 - L'Hospitalet/ES
  • 3 Medical Oncology, Institut Catala de Oncologia, 8907 - Barcelona/ES
  • 4 Department Of Medical Oncology, Catalan Institute of Oncology (ICO), Hospital Duran i Reynals, ONCOBELL, IDIBELL, 08907 - L'Hospitalet Barcelona/ES
  • 5 Medical Oncology, ICO - Institut Catala d'Oncologia Hospital Duran i Reynals, 08907 - Hospitalet de Llobregat/ES
  • 6 Gynaecology, Hospital Universitari Bellvitge, 08907 - Hospitalet de Llobregat/ES
  • 7 Radiology, Hospital Universitari Bellvitge, 08907 - Hospitalet de Llobregat/ES
  • 8 Patholoy, Hospital Universitari Bellvitge, 08907 - Hospitalet de Llobregat/ES
  • 9 Pathology, Hospital de Bellvitge, 08907 - Hospitalet de Llobregat/ES
  • 10 Unitat Assaigs Clinics, ICO - Institut Catala d'Oncologia Hospital Duran i Reynals, 08907 - L'Hospitalet Barcelona/ES
  • 11 Medical Oncology, Bellvitge Biomedical Research Institute (IDIBELL), 08908 - Hospitalet de Llobregat/ES
  • 12 Medical Oncology, Institut Català d'Oncologia Hospital Duran i Reynals, 08907 - Barcelona/ES


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5871


Neoadjuvant chemotherapy offers the possibility to test chemo sensitivity in vivo. pCR is a good surrogate of survival. Other measures of pathological response include de residual cancer burden (RCB). The aim of our study is to assess prognostic factors of survival including RCB.


488 breast cancer (BC) patients treated with NATC based on anthracyclines and taxanes with trastuzumab in HER-2 positive between 2009 and 2016 at a single Institution. Chi-square test was run for the univariate analyses and a cox-regression was performed regarding prognostic factors. Survival was calculated with Kaplan-Meier survival plots since the start of NATC to the first documented disease recurrence (DDFS) or overall survival (OS) by using IBM SPSS version 23.


Mean age was 51.13 (24-84). After a follow up of 63 (4-129) months there have been 14 (2.9%) local recurrences; 55 (11.3%) distant recurrences and 56 deaths (11.4%), 50 due to BC progression (10.2%). In the univariate analyses those factors related to distant recurrence were histology ductal vs lobular: 14.2 vs 35.7%, p: 0.032; molecular subtype: luminal A (15.2%) vs luminal B (14.2%) vs luminal B Her2 (11.8%) vs HER2 enriched (7.7%) vs triple negative (TN) (22.8%), p: 0.042; TstageT0 (0%), T1(12.5%), T2(12.3%), T3 (18.8%) and T4 (23.9%), p: 0.006; N stage N0 (9.6); N1 (12.8), N2 (17.5) and N3(27.3%), p = 0.063;pTstage pT0 (8.5%), pTis (9.7) pT1a+b(7.5%)pT1c(20.3 %), pT2(21.8%), pT3 (29.2%) and pT4 (100%), p = 0.000; pN stage pN0 (8.2); pN1mic (0%), pN1 (16.8), pN2 (32.2) and pN3(42.3%), p = 0.000 and the RCB 0 (3.2%) vs I (7.1%) vs II (16.5%) vs III (23.4%), p: 0.0001. The estimated 5y DDFS was for RCB0: 100%; RCBI: 98%; RCBII: 85% and RCBIII: 68%. The HR for RCB was 1.4 (95%IC, 1.2-1.6), per subgroups the log rank was for luminal A: 3.4, p: 0.330; for luminal B: 10.6, p: 0.03; for luminal B Her2: 7.9, p: 0.04; for Her2 enriched: 25, p: 0.000 and for TN 16, p: 0.003.


In our large series the RCB is reproducible as a surrogate of survival special in those chemo sensitive tumors such as Her2 and triple negative ones.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.